Gemini Therapeutics Inc
NASDAQ:GMTX
Gemini Therapeutics Inc
Common Shares Outstanding
Gemini Therapeutics Inc
Common Shares Outstanding Peer Comparison
Competitive Common Shares Outstanding Analysis
Latest Figures & CAGR of Competitors
Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
G
|
Gemini Therapeutics Inc
NASDAQ:GMTX
|
Common Shares Outstanding
$17.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Abbvie Inc
NYSE:ABBV
|
Common Shares Outstanding
$1.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Common Shares Outstanding
$1.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
Amgen Inc
NASDAQ:AMGN
|
Common Shares Outstanding
$536.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Common Shares Outstanding
$258.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Common Shares Outstanding
$110.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
See Also
What is Gemini Therapeutics Inc's Common Shares Outstanding?
Common Shares Outstanding
17.4m
USD
Based on the financial report for Dec 31, 2022, Gemini Therapeutics Inc's Common Shares Outstanding amounts to 17.4m USD.
What is Gemini Therapeutics Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 1Y
303%
Over the last year, the Common Shares Outstanding growth was 303%.